These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 21311328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Foreword. Poly(ADP-ribose) polymerase inhibitors in clinical development.
    Kummar S.
    Curr Probl Cancer; 2011; 35(1):6. PubMed ID: 21300206
    [No Abstract] [Full Text] [Related]

  • 3. Novel agents and future directions for refractory breast cancer.
    Burstein HJ.
    Semin Oncol; 2011 Jun; 38 Suppl 2():S17-24. PubMed ID: 21600381
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy in patients with castration-resistant prostate cancer.
    Meulenbeld HJ, Hamberg P, de Wit R.
    Eur J Cancer; 2009 Sep; 45 Suppl 1():161-71. PubMed ID: 19775615
    [No Abstract] [Full Text] [Related]

  • 5. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
    Trofimova I, Dimtchev A, Jung M, Rosenthal D, Smulson M, Dritschilo A, Soldatenkov V.
    Cancer Res; 2002 Dec 01; 62(23):6879-83. PubMed ID: 12460902
    [Abstract] [Full Text] [Related]

  • 6. PARP inhibitors in breast cancer.
    Telli ML, Ford JM.
    Clin Adv Hematol Oncol; 2010 Sep 01; 8(9):629-35. PubMed ID: 21157412
    [Abstract] [Full Text] [Related]

  • 7. Combined castration and androgen blockade therapy in prostate cancer. Conclusions.
    Denis L, Mettlin C.
    Cancer; 1990 Sep 01; 66(5 Suppl):1086-9. PubMed ID: 2203520
    [No Abstract] [Full Text] [Related]

  • 8. Targeted therapy for advanced prostate cancer: Looking through new lenses.
    Vogiatzi P, Cassone M, Claudio L, Claudio PP.
    Drug News Perspect; 2009 Dec 01; 22(10):593-601. PubMed ID: 20140279
    [Abstract] [Full Text] [Related]

  • 9. State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey.
    DiPaola RS, Kumar P, Hait WN, Weiss RE.
    N J Med; 2001 Feb 01; 98(2):23-33. PubMed ID: 11221439
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER.
    Curr Opin Pharmacol; 2006 Aug 01; 6(4):364-8. PubMed ID: 16753340
    [Abstract] [Full Text] [Related]

  • 11. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C, Low JA.
    Curr Opin Investig Drugs; 2007 Dec 01; 8(12):1051-6. PubMed ID: 18058575
    [Abstract] [Full Text] [Related]

  • 12. Castration-refractory prostate cancer: New drugs in the pipeline.
    Schrijvers D, Van Erps P, Cortvriend J.
    Adv Ther; 2010 May 01; 27(5):285-96. PubMed ID: 20532721
    [Abstract] [Full Text] [Related]

  • 13. Role of targeted therapy in the treatment of advanced prostate cancer.
    Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M.
    BJU Int; 2010 Mar 01; 105(6):748-67. PubMed ID: 20353536
    [Abstract] [Full Text] [Related]

  • 14. Targeted therapies in breast cancer: where are we now?
    Di Cosimo S, Baselga J.
    Eur J Cancer; 2008 Dec 01; 44(18):2781-90. PubMed ID: 19013786
    [Abstract] [Full Text] [Related]

  • 15. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
    Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.
    Clin Cancer Res; 1998 Aug 01; 4(8):1887-98. PubMed ID: 9717816
    [Abstract] [Full Text] [Related]

  • 16. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
    Drew L, Fine RL, Do TN, Douglas GP, Petrylak DP.
    Clin Cancer Res; 2002 Dec 01; 8(12):3922-32. PubMed ID: 12473608
    [Abstract] [Full Text] [Related]

  • 17. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
    Bryant HE, Helleday T.
    Biochem Soc Trans; 2004 Dec 01; 32(Pt 6):959-61. PubMed ID: 15506935
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.
    J Natl Cancer Inst; 2011 Feb 16; 103(4):334-46. PubMed ID: 21183737
    [Abstract] [Full Text] [Related]

  • 19. Maximizing outcomes in genitourinary cancers across the treatment continuum.
    Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A.
    BJU Int; 2011 Apr 16; 107 Suppl 2():1-12. PubMed ID: 21382149
    [Abstract] [Full Text] [Related]

  • 20. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
    Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI, American Society of Clinical Oncology.
    J Clin Oncol; 2007 Nov 20; 25(33):5313-8. PubMed ID: 17925542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.